TY - JOUR T1 - Trends and Intensity of Human Rhinovirus Invasions in Kilifi, Coastal Kenya Over a Twelve-Year Period, 2007-2018 JF - medRxiv DO - 10.1101/2021.08.03.21261536 SP - 2021.08.03.21261536 AU - John Mwita Morobe AU - Everlyn Kamau AU - Nickson Murunga AU - Winfred Gatua AU - Martha M. Luka AU - Clement Lewa AU - Robinson Cheruiyot AU - Martin Mutunga AU - Calleb Odundo AU - D James Nokes AU - Charles N. Agoti Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/08/04/2021.08.03.21261536.abstract N2 - Background Human rhinovirus (HRV) is an ubiquitous pathogen and the principal etiologic agent of common cold. Despite the high frequency of HRV infections, data describing its long-term epidemiological patterns in a single population remain limited.Methods We analysed 1,070 VP4/VP2 genomic region sequences obtained from samples collected between 2007-2018 from hospitalised paediatric patients (< 60 months) with acute respiratory disease in Kilifi County Hospital on the Kenya Coast.Results Of 7,231 children enrolled, HRV was detected in 1,497 (20.7%) andVP4/VP2 sequences were recovered from 1,070 samples (71.5%). A total of 144 different HRV types were identified (67 HRV-A, 18 HRV-B and 59 HRV-C) and at any time-point, several types co-circulated with alternating predominance. Within types multiple genetically divergent variants were observed. Ongoing HRV infections appeared to be a combination of (i) persistent types (observed up to seven consecutive months), (ii) reintroduced genetically distinct variants and (iii) new invasions (average of 8 new types, annually).Conclusion Sustained HRV presence in the Kilifi community is mainly due to frequent invasion by new types and variants rather than prolonged circulation of locally established strains.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by The Wellcome Trust, United Kingdom (grant 102975). The funder had no role in other aspects of the study including its design, data collection, data analysis, data interpretation, or writing of this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the study protocol was obtained from the Scientific and Ethics Review Unit (SERU # 3443) ethics committee, Kenya Medical Research Institute, Nairobi, Kenya.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated and analysis script for this manuscript are available from the Virus Epidemiology and Control (VEC), KEMRI-Wellcome Trust Research Programme, data server under the DOI: https://doi.org/10.7910/DVN/OL399P https://doi.org/10.7910/DVN/OL399P ER -